It is currently looking unlikely that Chiesi’s Lamzede will become routinely available on the NHS for patients with alpha-mannosidosis, after cost-regulators issued a preliminary rejection of the drug.
Tax rises will likely be needed to keep the quality of health and social care as it is now while the system contends with the growing demands of an ageing demographic, concludes a report by The Institute for Fiscal Studies and the Health Foundation.
The European Commission has expanded the scope of Amgen’s PCSK9 inhibitor Repatha to include the reduction of cardiovascular risk in adults with established atherosclerotic cardiovascular disease (CVD).
Novo Nordisk’s Refixia has come out on top in a head to head study assessing its effect in patients with the bleeding disorder haemophilia B against Swedish Orphan Biovitrum’s recombinant factor IX-Fc fusion protein (rFIXFc).
GlaxoSmithKline has released long-term data showing that its biologic Nucala significantly decreased exacerbations in patients with severe, eosinophilic asthma as well as improvement in disease control.